5-hydroxytryptamine receptor 6 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-135-hydroxytryptamine receptor 6 shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P50406. Start with Alzheimer disease, then reuse UniProt P50406 as the stable protein anchor across project notes and exports.
Start with Alzheimer disease, then reuse UniProt P50406 as the stable protein anchor across project notes and exports.
5-hydroxytryptamine receptor 6 shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include CERLAPIRDINE, IDALOPIRDINE, INTEPIRDINE, MASUPIRDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxy5-hydroxytryptamine receptor 6
Review this target as 5-hydroxytryptamine receptor 6, mapped to UniProt P50406. Sequence length is 440 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 5-hydroxytryptamine receptor 6 as ChEMBL target CHEMBL3371, mapped to UniProt P50406. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether 5-hydroxytryptamine receptor 6 is the right protein anchor across sources, using UniProt P50406 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Alzheimer disease is currently framed as late clinical support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | 5-hydroxytryptamine receptor 6 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P50406 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | 5-hydroxytryptamine receptor 6 |
| UniProt Accession | P50406 |
| Component Type | Protein |
| Sequence Length | 440 aa |
5-hydroxytryptamine receptor 6
Review this target as 5-hydroxytryptamine receptor 6, mapped to UniProt P50406. Sequence length is 440 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
5-hydroxytryptamine receptor 6 shows late clinical disease relevance led by Alzheimer disease. 3 more disease programs remain visible in the same review block.
Start review with Alzheimer disease because it currently carries late clinical support. Linked drugs include CERLAPIRDINE, IDALOPIRDINE, INTEPIRDINE, MASUPIRDINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3329438 | 10.4 | Ki | 0.04 | Preclinical |
| CHEMBL3785512 | 10.3 | Kd | 0.05012 | Preclinical |
| CHEMBL3692995 | 10.3 | Ki | 0.05 | Preclinical |
| CHEMBL1084794 | 10.3 | Ki | 0.05012 | Preclinical |
| CHEMBL398034 | 10.2 | Ki | 0.0631 | Preclinical |
| CHEMBL1085462 | 10.2 | Ki | 0.0631 | Preclinical |
| CHEMBL362628 | 10.19 | EC50 | 0.06457 | Preclinical |
| CHEMBL5894995 | 10.18 | IC50 | 0.066 | Preclinical |
| CHEMBL6037204 | 10.13 | IC50 | 0.074 | Preclinical |
| CHEMBL1086326 | 10.1 | Ki | 0.07943 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 357 | 964 | 7.7 |
| cell-based format | 273 | 2,556 | 7.4 |
| cell membrane format | 25 | 405 | 7.5 |
| assay format | 8 | 285 | 8.4 |
| mitochondrion format | 1 | 22 | 8.2 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 180 | 856 | 7.2 |
| assay format | 26 | 33 | 7.7 |
| cell membrane format | 3 | 24 | 7.2 |
| single protein format | 2 | 1 | 8.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 4 | 18 | 6.4 |
| single protein format | 1 | 0 | — |